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ABSTRACT Transgenic micewere generatedwith cardiac-
specific overexpression of the G protein-coupled receptor
kinase-5 (GRK5), a serine/threonine kinase most abundantly
expressed in the heart compared with other tissues. Animals
overexpressing GRK5 showed marked ,I-adrenergic receptor
desensitization in both the anesthetized and conscious state
compared with nontransgenic control mice, while the con-
tractile response to angiotensin II receptor stimulation was
unchanged. In contrast, the angiotensin 11-induced rise in
contractility was significantly attenuated in transgenic mice
overexpressing the 13-adrenergic receptor kinase-1, another
member of the GRK family. These data suggest that myocar-
dial overexpression ofGRK5 results in selective uncoupling of
G protein-coupled receptors and demonstrate that receptor
specificity of the GRKs may be important in determining the
physiological phenotype.
action between residues within /ARK's carboxyl terminus and
the dissociated, membrane-anchored fry subunits of G pro-
teins (11, 12). Unlike PARK1, GRKS does not undergo
agonist-dependent translocation from cytosol to membrane,
but rather is constitutively membrane-bound (10). Previous in
vitro reconstitution and intact cell experiments have demon-
strated agonist-dependent phosphorylation of many G pro-
tein-coupled receptors by various GRKs, including f31-ARs,
the predominant subtype in the heart (13-15). Since the
myocardial 13-AR system is so critical in normal and patho-
physiologic states (8, 9), we sought to determine the extent and
specificity to which targeted cardiac overexpression of GRK5
would desensitize G protein-coupled receptors in vivo. Fur-
thermore, since myocardial function is greatly influenced by
anesthetic agents, studies were also performed in chronically
instrumented transgenic mice in the awake, conscious state.
A diverse family of receptors activate G protein-coupled signal
transduction pathways to elicit multiple biologic functions.
Two G protein-coupled receptors that are closely involved in
the regulation of cardiac function and growth in response to
neurohormonal and mechanical stimuli are the ,13-adrenergic
receptor (X31-AR) and the angiotensin II (AnglI) receptor (1,
2). These receptors, when activated by agonists, stimulate the
heterotrimeric G proteins Gs and Gq, respectively, leading to
the intracellular accumulation of second messengers; notably,
cAMP from f31-AR-Gs coupling and inositol trisphosphate
and diacylglycerol from AngII-Gq coupling (3, 4). With
persistent stimulation by agonist, many G protein signal trans-
duction systems demonstrate diminished responsiveness re-
ferred to as desensitization. Two classes of serine/threonine
kinases can regulate receptors through rapid receptor phos-
phorylation; the second messenger-activated protein kinases,
such as the cAMP-dependent protein kinase and protein
kinase C (5), and the G protein-coupled receptor kinases
(GRKs), which phosphorylate activated receptors, leading to
homologous desensitization (5). Currently there are six known
members of the emerging GRK family, of which GRK2
(commonly known as ,BARK1), GRK3, GRK5, and GRK6 are
expressed in the heart (6, 7). Previous studies have shown that
,BARK1 is a critical in vivo regulator of cardiac function (8),
and it is elevated in chronic human heart failure (9). GRK5, as
shown by Northern analysis, is most abundantly expressed in
the heart compared with other tissues (10), although its impor-
tance in myocardial 83-AR signaling has not been established.
Several unique features distinguish agonist-induced desen-
sitization mediated by these two GRKs (P3ARK1 and GRK5).
The primarily cytosolic fARK1 requires a membrane-
targetingortranslocation eventbefore phosphorylating agonist-
occupied receptors, which occurs via a direct physical inter-
METHODS
Generation and Identification of Transgenic Mice. Trans-
genic mice were created using the a-myosin heavy chain
promoter to direct cardiac-specific overexpression of the entire
coding region for bovine GRK5. For construction of the GRK5
transgene, the 1.8-kb EcoRI-XbaI open reading frame was
isolated from a previous constructed plasmid (10) and ligated
into a plasmid containing the SV-40 intron poly(A) signal (8)
to yield pGEM-GRK5-SV-40. This construct was then digested
with EcoRI, blunted with Klenow DNA polymerase and
subsequently digested with Sacl. A SacI-blunt 5.5-kb a-myosin
heavy chain promoter (16) cassette was then ligated into this
plasmid to generate the plasmid pGEM-aMHC-GRK5-SV-40.
The transgene was then linearized and purified before pro-
nuclear injections done by the Duke Comprehensive Cancer
Center Transgenic Facility (8). Two lines were established, TG
GRK5-25 and TG GRK5-45. Litter sizes and postneonatal
development was indistinguishable from nontransgenic litter-
mate controls. Offspring were screened by Southern blot
analysis with a probe to the SV-40 sequences. Second gener-
ation adult animals, 2-5 months of age from the TG GRK5-45
line were used for all physiological studies. Institutional Re-
view Board approval for all mouse experiments was obtained
from the University of California at San Diego and from Duke
University.
Western Analysis. Immunodetection of myocardial levels of
GRK5 in control nontransgenic and transgenic mice was
performed in solubilized myocardial membranes followed by
Abbreviations: /31-AR, ,13-adrenergic receptor; AngII, angiotensin II;
GRK, G protein-coupled receptor kinase; LV, left ventricle; L-
NAME, N-nitro-L-arginine methyl ester; AT,, angiotensin II type 1
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immunoprecipitation. Myocardial extracts were prepared by
homogenization of excised hearts in ice-cold lysis buffer (2 ml
of 25 mM Tris Cl, pH 7.5/5 mM EDTA/5 mM EGTA/10 ,ug
of leupeptin per ml/20 ,ug of aprotinin per ml/1 mM phenyl-
methylsulfonyl fluoride) and centrifuged at 48,000 x g for 30
min. The supernatants that contain soluble kinases (i.e.,
/3ARK1 and overexpressed GRK5) were discarded and the
membranes rehomogenized in ice-cold solubilization buffer (2
ml of 50 mM Tris Cl, pH 8.0/150 mM NaCl/5 mM EDTA/1%
Nonidet P-40/0.5% sodium deoxycholate/0.1% SDS/10 mM
NaF/10 mM sodium pyrophosphate/0.1 mM phenylmethyl-
sulfonyl fluoride) and clarified by centrifugation. GRK5 was
immunoprecipitated from 1 ml of clarified extract with 1:500
(2 ,ul) anti-GRK5 serum (10) and 35 ,ul of a 50% slurry of
protein A-agarose conjugate agitated for 1 hr at 4°C. Immune
complexes were washed five times with ice-cold solubilization
buffer, and the dried agarose beads were resuspended in 30 ,ul
of protein-gel loading buffer and electrophoresed through
SDS/12% polyacrylamide gels and transferred to nitrocellu-
lose. The endogenously and exogenously overexpressed -68-
kDa GRK5 protein was visualized with a monoclonal antibody
raised against an epitope within the carboxyl terminus of
bovine GRK5, and detection of anti-mouse IgG conjugated
with horseradish peroxidase was carried out by enhanced
chemiluminescence (ECL; Amersham).
GRK Activity in Rhodopsin Phosphorylation Assays. Hearts
were homogenized as described above. The first supernatant
was removed, and the pelleted membranes were rehomog-
enized in lysis buffer containing 250 mM NaCl, to dissociate
membrane-bound kinase (i.e., GRK5), and centrifuged at
48,000 x g for 30 min. The membrane protein supernatant was
further purified by adding a slurry of 50% (vol/vol) diethyl-
aminoethyl Sephacel (pH 7.0) in the presence of 250mM NaCl,
incubated on ice for 30 min, and run over a small disposable
column. Final supernatants were eluted with no salt buffer and
concentrated using a Centricon (Amicon) microconcentrator.
Protein concentration was determined by Bradford assay (17).
Concentrated membrane extracts (50 ,ug of protein) were
incubated with rhodopsin-enriched rod outer segments (8) in
lysis buffer (75 ,ul) with 10 mM MgCl2 and 0.1 mM ATP
(containing [y-32P]ATP). After incubating in white light for 15
min at room temperature, reactions were quenched with ice
cold lysis buffer (300 ,ul) and centrifuged for 15 min at 13,000 x
g. Sedimented proteins were resuspended in 25 Al of protein-
gel loading dye and electrophoresed through SDS/12% poly-
acrylamide gels (8). Phosphorylated rhodopsin was visualized
by autoradiography of dried polyacrylamide gels and quanti-
fied using a Phoshorlmager (Molecular Dynamics).
Adenylyl Cyclase Activity. Myocardial sarcolemmal mem-
branes were prepared by homogenizing whole hearts in ice-
cold cyclase buffer (50mM Hepes, pH 7.3/150mM KCl/5 mM
EDTA). Nuclei and tissue were separated by centrifugation at
800 x g for 10 min, and the crude supernatant was then
centrifuged at 20,000 x g for 10 min. Sedimented proteins were
resuspended at a concentration of 2-3 mg of protein per ml in
assay buffer (50 mM Hepes, pH 7.3/5 mM MgCl2). Mem-
branes (20-30 ,ug of protein) were incubated for 15 min at 37°C
under basal conditions and in the presence of isoproterenol or
NaF and cAMP was quantitated by standard methods de-
scribed previously (8).
Physiological Evaluation. Hemodynamic evaluation in anes-
thetized mice. Mice were anesthetized with a mixture of ket-
amine and xylazine (8, 18). After endotracheal intubation,
mice were connected to a rodent ventilator. Either carotid
artery was cannulated with a flame-stretched PE-50 catheter
connected to a modified P-50 Statham transducer. Following
bilateral vagotomy, the chest was opened, and either a 1.8-
French or 2-French high-fidelity micromanometer catheter
was inserted into the left atrium, advanced through the mitral
valve, and secured in the left ventricle (LV). Hemodynamic
measurements were recorded at baseline and 45-60 sec after
injection of incremental doses of isoproterenol or AngIl.
Doses of isoproterenol were specifically chosen to maximize
the contractile response but limit the increase in heart rate.
Continuous high-fidelity LV and fluid-filled aortic pressure
was recorded simultaneously at baseline and 45-60 sec after
each dose of agonist on an eight-channel chart recorder and in
digitized form at 2000 Hz for later analysis. Experiments were
then terminated with an overdose of pentobarbital. Hearts
were rapidly excised, and individual chambers were separated,
weighed, and then frozen in liquid N2 for later analysis.
Parameters measured were heart rate, aortic pressure, LV
systolic and end diastolic pressure, and the maximal and minimal
first derivative of LV pressure (LV dP/dtmax, dP/dtmin). Ten
sequential beats were averaged for each measurement. The TG
GRK5-45 and TG ,BARK12 (8) lines were used for all in vivo
physiological studies of 13-AR and AngII receptor function.
Alterations in loading conditions. To determine the effect of
acute changes in loading conditions on contractile function,
LV systolic pressure was acutely increased in control mice (n =
4) with administration of the nitric oxide synthase inhibitor,
N-nitro-L-arginine methyl ester (L-NAME). Following instru-
mentation, hemodynamic measurements were continuously
recorded under basal conditions and after progressive intra-
venous doses (0.025-2.5 mg) ofL-NAME and analyzed as above.
Hemodynamics in conscious mice. For measurement of he-
modynamic parameters in the conscious state, mice were
anesthetized with the same mixture of ketamine and xylazine
and were allowed to breathe spontaneously. A 1.8-French
high-fidelity micromanometer catheter was inserted into the
right carotid and advanced retrograde into the LV. The
catheter was secured in the neck and tunneled to the back and
exteriorized. Mice were allowed to recover from anesthesia
(1.5-2 hr), and hemodynamic measurements were recorded in
the quiet resting awake state. Hemodynamic parameters were
analyzed as above.
Statistical Analysis. Data are expressed as mean values ±
SEM. To examine the effect of the various agonists on changes
in hemodynamic parameters between the control and TG
GRK5-45 groups, a two-way repeated measures (isoprotere-
nol, Angll) or a one factor (L-NAME) analysis of variance
(ANOVA) was used. Post hoc analysis with regard to differ-
ences in mean values between the groups at a specific dose
were conducted with a Newman-Keuls test. To test for sta-
tistical significance of physiological parameters in conscious
mice following recovery from anesthesia a two-way repeated
measures ANOVA for two comparisons was used with a
Newman-Keuls post hoc analysis. A Student's t test was used
to test for statistical difference in adenylyl cyclase activities.
For all analyses, P < 0.05 was considered significant.
RESULTS
The extent of overexpression ofGRK5 mRNA for the two lines
of transgenic mice was first determined by Northern analysis
(data not shown). Membrane-bound GRK5 protein was iden-
tified in control nontransgenic and GRK5 overexpressing
animals via solubilization of cardiac membranes and immu-
noprecipitation of GRK5 followed by visualization by Western
blotting (Fig. -A). Increased GRK5 protein in the heart
resulted in both lines of transgenic mice (Fig. 1A). To quantify
the activity of membrane-bound GRK in transgenic mice, the
membrane fractions from heart extracts were assayed for
ability to catalyze the phosphorylation of the G protein-
coupled receptor rhodopsin. Consistent with the marked over-
expression of GRK5 protein, there was a marked increase in
kinase activity in the membrane fraction of extracts from TG
GRK5-45 (Fig. 1B). This kinase activity in the membrane
fraction is presumed to be primarily GRK5, since the addition
of purified fy subunit of G protein, which activates ,BARK1,
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Proc. Natl. Acad. Sci. USA 93 (1996)
A
--- 80 Kd
B
_- Rho
FIG. 1. Assessment of GRK5 expression and activity. (A) Immu-
nodetection of myocardial levels of GRK5 in membrane extracts from
control nontransgenic and transgenic mice. The endogenous and
exogenously overexpressed 68-kDa GRK5 protein was visualized via
Western blotting and chemiluminescence. The 80-kDa marker is
shown. (B) Assessment of GRK activity in the membrane fraction of
extracts from control and transgenic hearts using a rhodopsin phos-
phorylation assay. Shown is a representative autoradiograph of a dried
gel where phosphorylated rhodopsin (Rho) is visualized.
did not lead to enhanced activity (data not shown). From these
data, it was found that the TG GRK5-45 line had >30-fold
overexpression of myocardial GRK5 compared with the levels
of this kinase found in the hearts of nontransgenic control mice.
To examine the biochemical effects of this marked GRK5
overexpression on the myocardial ,3-AR system, we assessed
receptor-effector coupling in sarcolemmal membranes from
control and transgenic mouse hearts by measuring adenylyl
cyclase activity under basal conditions and after maximal doses
of isoproterenol and NaF (Table 1). In cardiac membranes
from TG GRK5-45 mice, basal adenylyl cyclase activity as well
as isoproterenol-stimulated activity, was significantly lower
(Table 1). NaF-stimulated values were slightly lower in the TG
GRK5-45 mice but did not reach statistical significance (Table
1). In addition, the density of myocardial ,3-ARs was found to
be unchanged in the hearts ofTG GRK5-45 animals (data not
shown). Thus, there appears to be functional uncoupling of
myocardial ,B-ARs due to the overexpression of GRK5, which
Table 1. Adenylyl cyclase activity in control and TG
GRK5-45 hearts
Activity, pmol/min per mg
Hearts Basal ISO, 10-4 M NaF, 10-3 M
Control, n = 5 45.1 ± 6.4 102.8 ± 17.2 364.5 ± 43.0
TG GRK5-45, n = 8 21.2 ± 4.1* 31.8 ± 5.5* 285.3 ± 37.5
ISO, isoproterenol.
*P < 0.05 compared to control.
indicates that, like ,BARK1 (8), GRK5 can desensitize myo-
cardial 13-ARs.
To directly assess whether overexpression of GRK5 uncou-
ples ,3-ARs, cardiac catheterization was used to measure
catecholamine responsiveness in vivo in the intact anesthetized
mouse (Fig. 2). Continuous measurements of heart rate and
LV pressures were recorded before and after progressive doses
of isoproterenol. At baseline, reduced LV systolic pressure and
slower LV relaxation was observed in the TG GRK5-45 mice
compared with control animals (Fig. 2 B and C). Marked
blunting of the isoproterenol-induced inotropic response (Fig.
2A), as well as an attenuated fall in LV dP/dtmin, was seen with
13-AR stimulation (Fig. 2B). The rise in LV systolic pressure
was blunted compared with littermate controls (Fig. 2C)
without a change in heart rate (Fig. 2D). LV end diastolic
pressure was not statistically different between groups at
baseline (control 4.3 ± 0.4 versus transgenic 2.9 ± 0.5 mmHg;
1 mmHg = 133 Pa) or with isoproterenol (control 8.0 ± 0.6
versus transgenic 6.0 ± 0.8 mmHg for the maximal dose).
These data suggest that in vivo, myocardial f3-ARs are targets
for the membrane-bound GRK5 induced receptor phosphor-
ylation and desensitization.
Because baseline contractility and responsiveness to sym-
pathetic stimulation can be profoundly altered by general
anesthesia (19, 20), hemodynamic evaluation was performed in
chronically instrumented mice in the fully awake resting state.
In control mice, recovery from anesthesia was associated with
a significant increase in LV dP/dtm., LV dP/dtmin, and heart
rate (Table 2). In contrast, enhancement of contractile func-
tion with recovery from anesthesia was significantly blunted in
theTG GRK5-45 mice (Table 2). Heart rate was similar in both
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FIG. 2. In vivo assessment of LV contractile function of TG
GRK5-45 (n = 10) (-) and nontransgenic littermate control mice (n =
13) (0). Cardiac catheterization was performed in intact anesthetized
animals. Four measured parameters are shown at baseline and after
progressive doses of isoproterenol. (A) LV dP/dtm.a; (B) LV dP/dtmin;
(C) LV systolic pressure; and (D) heart rate. Data were analyzed with
a two-way repeated ANOVA. *, P < 0.001; and t, P < 0.05; control
versus transgenic. A significant between-group main effect in response
to isoproterenol was found for (A) dP/dtmax (P < 0.0005); (B) dP/dtmin
(P < 0.001); and (C) LV systolic pressure (P < 0.001). The pattern of
change between groups was statistically different for (B) dP/dtmin, P <
0.05.
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groups (Table 2). These results demonstrate that marked
83-AR uncoupling and desensitization with GRK5 overexpres-
sion can significantly depress contractile function in mice with
an integrated autonomic nervous system.
To determine whether GRK5 overexpression uncouples
other G protein-coupled receptors, in vivo hemodynamic
assessment was used to measure the physiologic response to
AnglI (Fig. 3). A sharp rise in LV systolic pressure in both
transgenic mice and negative littermates resulted in response
to infusion of progressive doses of AngII documenting the
potent vasoconstrictor action of this neurohormone (Fig. 3C).
Associated with the peripheral hemodynamic action of AngII,
the effect on cardiac function included an increase in LV
dP/dtmax (Fig. 3A) and LV dP/dtmin (Fig. 3B) without a change
in heart rate (Fig. 3D), consistent with the known character-
istics of AnglI on myocardial function (21). However, no
difference was observed between the TG GRK5 mice com-
pared with nontransgenic controls in the response to admin-
istered AngIl (Fig. 3), indicating that despite the extraordi-
narily high levels of GRK5 expressed in the hearts of these
animals, no AnglI receptor desensitization is apparent. LV end
diastolic pressure was also not statistically different between
groups at baseline (control 1.2 ± 0.5 versus transgenic 0.8 ±
0.3 mmHg) or with AngII (control 4.6 ± 0.8 versus transgenic
3.2 ± 0.4 mmHg maximal dose). Thus, these data strongly
suggest that myocardial overexpression of GRK-5 results in
selective uncoupling of G-protein coupled receptors in vivo.
As described above, we have previously reported increased
desensitization of the (3-AR in transgenic mice with cardiac
overexpression of ,BARK1 due to a decrease in functional G
protein coupling of receptors (8). Since overexpression of
GRK5 results in selective uncoupling of myocardial G protein-
coupled receptors, we asked the question whether this was
unique to GRK5, or could it be a property of other members
of the family. In vivo physiologic measurements, in response to
infusions of AngII were performed in transgenic animals that
overexpress cardiac targeted ,BARK1 (TG fBARK12). In con-
trast to the GRK5 overexpressing animals, the AngII-induced
rise in LV dP/dtm. was significantly attenuated in the TG
,BARK12 mice compared with nontransgenic littermate con-
trols (Fig. 4A). The enhancement of relaxation with AngII
administration was also attenuated (Fig. 4B). The increase in
LV systolic pressure was similar in both groups, except for the
highest dose of AngII, which was slightly lower in the TG
f3ARK12 mice (Fig. 4C). Heart rate in the TG fARK12 mice
was significantly lower at all time points compared with
controls but was unaffected by AnglI infusion (Fig. 4D). LV
end diastolic pressure was not statistically different between
groups at baseline (control 4.4 ± 0.6 versus transgenic 6.2 +
1.1 mmHg) or with AngII (control 8.0 ± 0.8 versus transgenic
9.1 ± 0.8 mmHg for the maximal dose). Thus, these in vivo
effects seen in TG ,BARK12 animals indicate that the cardiac
AngII receptor is a target for f3ARK1-mediated desensitiza-
tion and demonstrates a significant qualitative difference in
the in vivo substrates of these two GRKs.
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FIG. 3. In vivo assessment of LV function ofTG GRK5-45 (n = 15)
(0) and nontransgenic control mice (n = 17) (0) in response to
progressive doses of AngII. Cardiac catheterization was performed
and the following parameters are shown: (A) LV dP/dtmax; (B) LV
dP/dtmin; (C) LV systolic pressure; and (D) heart rate. No significant
difference between groups was found in response to AngII (ANOVA).
In both groups, a significant difference was found for both the AngII
2-ng and 10-ng dose compared with their respective basal levels for (A)
dP/dtmax (P < 0.001); (B) dP/dtmin (P < 0.01); and (C) LV systolic
pressure (P < 0.01).
Although LV dP/dtm. is a sensitive index of contractility, it
is influenced by loading conditions, particularly preload (22).
Since LV end diastolic pressure was not significantly different
between groups for any of the above experiments, it is unlikely
that the observed alterations in receptor function were due to
differences in end diastolic pressure. To determine whether
acute changes in systolic loading conditions can affect LV
dP/dtmax, a pharmacological approach was used. In separate
experiments in control mice (n = 4), acute increase in LV
systolic pressure was achieved with progressive doses (0.025-
2.5 mg) of the nitric oxide synthase inhibitor L-NAME. As
shown in Fig. 5, LV dP/dtma, was unchanged (5271 ± 361 to
5116 ± 375 mmHg/sec) despite a 40 mmHg (73 ± 5 to 112 ±
8 mmHg) increase in LV systolic pressure after L-NAME
infusion. The increase in systolic pressure was similar to that
observed with AnglI infusion. These data suggest that systolic
loading conditions alone are unlikely to cause the above
findings and supports the conclusion that the AngII receptor
Table 2. Hemodynamic parameters in conscious mice following recovery from anesthesia
Control, n = 7 TG GRK5-45 n = 7
Parameter Anesthetized Conscious Anesthetized Conscious
LVSP, mmHg 93 ± 5 120 ± 4* 94 ± 4 110 ± 6*
LVEDP, mmHg 12.5 ± 1.5 5.7 ± 1.0* 9.3 ± 1.5 9.2 ± 2.0
LVdP/dtmax, mmHg/s 5432 ± 378 14773 ± 1303t 5024 ± 300 7998 ± 971tt
LVdP/dtmin, mmHg/s -4901 ± 183 -10487 ± 1270t -4866 ± 378 -5922 ± 802t
Heart rate, bpm 239 ± 13 481 ± 24t 185 ± 7 428 ± 38t
LVSP, LV systolic pressure; LVEDP, LV end diastolic pressure; LV dP/dtmax,,min, maximal and minimal
first derivative of LV pressure, respectively; and bpm, beats per min.
*P < 0.05, conscious versus anesthetized for either group.
tp < 0.001, conscious versus anesthetized for either group.
*P < 0.001, TG GRK5 conscious versus control conscious.
Physiology: Rockman et al.
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FIG. 4. Effect of AngII on in vivo LV function of transgenic mice
overexpressing,BARK1. Cardiac catheterization was performed in TG
,BARK12 (n = 9) (0) and negative control mice (n = 9) (0). Measured
parameters are shown at baseline and after progressive doses of AngII:
(A) LV dP/dtmax; (B) LV dP/dtmin; (C) LV systolic pressure; and (D)
heart rate. *, P < 0.001; and t, P < 0.05; control versus transgenic,
ANOVA. A significant between-group main effect in response to
AngII was found for (A) dP/dtma (P <0.001); (B) dP/dtmin (P <0.01);
and (D) heart rate (P < 0.05). The pattern of change between groups
was statistically significant for (A) dP/dtm. (P < 0.05); (B) dP/dtmin(P < 0.05); and (C) LV systolic pressure (P < 0.01).
is uncoupled in the TG 13ARK12 mice while it is not modified
in TG GRK5-45 mice.
DISCUSSION
This study demonstrates that desensitization of G protein-
coupled receptors in vivo by GRKs, such as GRK5, is not
uniform. Furthermore it appears that,BARK1 can affect at
least two divergent signaling pathways by uncoupling both the
13-AR and AngII receptor. These results provide an example
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FIG. 5. Effect of the nitric oxide synthase inhibitor L-NAME on
contractile function in control mice (n = 4). Simultaneous LV systolic
pressure (0) and LV dP/dtm. (0) are plotted before and after
progressive doses (0.025-2.5 mg) of L-NAME. Numbers on graph
represent LV end diastolic pressure at each time point, which were not
significantly different from basal. (*, P < 0.001 versus basal).
of the power of these transgenic animal models to elucidate
critical issues about physiological receptor specificity of the
important GRK enzymes.
The extent of diminution of the in vivo myocardial responses
to isoproterenol in these GRK5 overexpressing animals is
more pronounced than that of the responses in transgenic mice
with cardiac-specific overexpression of 13ARK1 (TG 1ARK12)
(8). This is likely attributable to the greater overexpression of
GRK5 in these animals (>30-fold) versus the 3- to 5-fold
increase over endogenous 1ARK1 in the TG J3ARK12 animals
(8). Importantly, these results demonstrate that a second
GRK, in addition to ,BARK1, can affect myocardial ,3-AR
signaling in vivo and hence regulate cardiac function.
Effect of Anesthesia. Baseline contractility and responsive-
ness to 13-AR stimulation may be profoundly altered by general
anesthesia (19, 20). Anesthesia depresses myocardial contrac-
tility and can significantly affect systolic and diastolic proper-
ties of the heart (23). Since autonomic mechanisms are im-
portant in the regulation of myocardial contractility under
conscious conditions, we tested whether GRK5 overexpression
would result in a cardiac phenotype similar to that found under
anesthetized conditions. Our data demonstrate that in the
conscious mouse, with integrated neurohumoral pathways,
forced overexpression of GRK5 chronically uncouples myo-
cardial 13-ARs.
The choice of anesthetic agent clearly influences the effect
on hemodynamic parameters. We used a combination of
ketamine and xylazine, which results in marked bradycardia
because of the CNS depression induced with xylazine. Indeed,
the bradycardia observed with anesthesia in our mice is quite
different than that reported with the use of barbiturate anes-
thetics, which tend to increase sympathetic activation (19, 20).
The recovery from anesthesia in mice used in this study, was
related to withdrawal of the central nervous system depression
and accounts for the dramatic increase in heart rate and
dP/dtmax in the awake mouse compared with that under
anesthesia. Furthermore these results illustrate an important
principle with respect to 13-AR signal transduction in that
receptor occupancy by agonist is a required process for ho-
mologous desensitization of the 13-AR (6, 12). The anesthetic
agents used in this study would depress sympathetic outflow
and result in low levels of norepinephrine, the endogenous
ligand for the 13-AR, which may account for only the small
difference in basal contractility between the TG GRK5 and
control mice. In contrast, recovery from anesthesia would be
associated with an increase in neuronal norepinephrine re-
lease, now interacting with uncoupled 13-ARs, to result in the
TG GRK5-45 cardiac phenotype. This process is also apparent
in the isoproterenol stimulation studies (Fig. 2).
Influence of Loading Conditions and Heart Rate. Increases
in either LV end diastolic pressure or heart rate will positively
influence LV dP/dtmax. In our studies, although LV end
diastolic pressure increased slightly with agonist infusion, no
difference was observed between the transgenic and control
groups, making it unlikely that the diminished LV dP/dtm.
response was the result of changes in preload alone. The small
increase in LV end diastolic pressure with isoproterenol
infusion is expected, since each mouse receives 500,ul of
volume for theagonist studies and would tend to counter the
expected fall in preload with 13-AR stimulation.
Heart rate will importantly affect contractile function as
shown in mice following recovery from anesthesia. Mice
overexpressing 13ARK1 had a significantly lower heart rate
compared with control mice. This likely results from atrial
expression of the transgene with the a-myosin heavy chain
promoter. It is interesting that heart rate was not different in
the TG GRK5 mice using the same promoter to drive expres-
sion and may relate to the ability of 13ARK1 to desensitize
other G protein-coupled receptors in vivo. Although the heart
rate under basal conditions is lower in the TG 13ARK12 mice,
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the response to Angll was very different for contractility, as
shown by the blunted increase in dP/dtmax compared with the
parallel downward shift in the heart rate curve. The different
pattern of change in the dP/dtmax response between the groups
is confirmed by the significant interaction effect in the
ANOVA analysis. These data imply that despite the small
difference in basal heart rate, the effect of AnglI on contractility
was significantly different between the transgenic and control
mice consistent with chronic uncoupling of the AT1 receptor.
Since AngII is known to stimulate release of catecholamines
from the adrenal medulla and peripheral sympathetic nerve
endings, it is possible that the increase in dP/dtmax was the
result of heightened ,3-AR stimulation (24). We feel this is
unlikely, since our data shows the TG GRK5 mice to have a
markedly desensitized ,3-AR signal pathway, which should
have blunted the effect of AnglI if it were mediated through
the ,B-AR. Thus, the mechanism for the increase in contractile
function with Angll infusion in our preparation is more likely
to be mediated through the Gq-coupled AT1 receptor, which
activates phospholipase C to generate the second messengers,
inositol trisphosphate, and diacylglycerol and stimulate intra-
cellular Ca2+ release (3, 4). Our results are also consistent with
in vitro studies demonstrating much greater effects of ,BARK1
than GRK5 on Angll receptor function in transfected cell
systems (14).
Implications. These results have important implications in
heart failure where elevated mRNA levels for ,BARK1 and
enhanced GRK activity (9) may act to desensitize /3-ARs,
leading to the characteristic observation of reduced /3-AR
responsiveness to catecholamines (25, 26). Our results suggest
that upregulation ofGRK5 in heart failure could contribute to
/3-AR uncoupling and may provide another attractive target
when attempting to modulate receptor desensitization in the
failing heart (27). Furthermore, this study suggests that in vivo,
enhanced receptor phosphorylation may not be limited to the
/3-AR but it can involve other G protein-coupled receptors.
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